Developer docs
API playgroundTry for free, no card

Search company profiles

Intact Therapeutics

Full company profile

uuid00039r4

Namestring
Intact Therapeutics
Legal namestring
Intact Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
localized drug delivery, gastrointestinal therapeutics, biopharmaceutical drug development, clinical-stage biopharmaceuticals, novel drug formulations
Industry1 code
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Gastrointestinal Therapeutics
No data
Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Clinical-stage biopharmaceutical company developing innovative medicines for gastrointestinal disease. Revenue model likely to include pharmaceutical product sales upon regulatory approval, potentially through licensing agreements or direct commercialization.

intacttherapeutics.com
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Intact Therapeutics is a clinical-stage biopharmaceutical company developing next-generation localized drug delivery technologies (smart gels / micelles-based formulations) for the treatment of gastrointestinal (GI) disease. The platform is designed to deliver therapeutics directly to GI tissue, addressing unmet clinical needs and aiming to improve efficacy and reduce systemic side effects relative to conventional systemic drug delivery. The company has no commercially approved products at this stage.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Intact Therapeutics is a clinical-stage biopharmaceutical company developing next-generation localized drug delivery technologies for gastrointestinal (GI) disease. The company operates as a single-focus therapeutic development organization without modular products or a platform-plus-components architecture — its portfolio consists of innovative medicines in development targeting GI diseases, though specific named products are not publicly disclosed on the available source pages.

Product and service1 record
1Localized Drug Delivery Platform (GI)
CategoryDrug Delivery Technology
Description

Proprietary next-generation localized drug delivery platform (smart gels / micelles-based) designed for targeted treatment of gastrointestinal diseases. The platform is being developed to deliver therapeutics directly to GI tissue with the goal of improving efficacy and reducing systemic side effects relative to conventional systemic drug delivery. Currently pre-clinical / clinical-stage with no approved products.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Stanford University, specifically through its SMC (Stanford Medicine Consortium) program, partners with Intact Therapeutics for research collaboration, academic expertise, and potential co-development opportunities in drug delivery technology.

2UCSF Rosenman Institute
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The UCSF Rosenman Institute, focused on health technology and innovation, provides strategic partnership for Intact Therapeutics including access to medical research expertise and potential clinical collaboration opportunities.

intacttherapeutics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Encube appears as a partner logo on the Intact Therapeutics website, indicating a strategic relationship possibly related to pharmaceutical development, manufacturing, or commercialization support.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty GI biopharmaceutical company (Linzess/linaclotide) focused on GI diseases — directly comparable in therapeutic area and stage evolution, though at a far larger commercial scale.

TypeDirect peer
Description

Specialty biopharma with a GI-dominant commercial portfolio (Talicia, Aemcolo) and pipeline — directly comparable as a small/mid-cap GI specialty therapeutics developer.

TypeEmerging player
Description

Clinical-stage synthetic biology company developing engineered probiotics for GI disorders (e.g., phenylketonuria, IBD) — emerging player using novel biology to address GI unmet need, comparable in stage and innovation orientation.

TypeBroad incumbent
Description

Major global biopharma with a leading GI franchise including Entyvio for IBD — broad incumbent comparable in target indications but vastly larger and broader in scope.

TypeBroad incumbent
Description

Through its Salix franchise, Bausch is a dominant established GI specialty pharma player — relevant incumbent comparable in therapeutic area but not in scale or technology specificity.

TypeDirect peer
Description

Late-stage GI specialty biopharma (Voquezna for H. pylori and erosive esophagitis) — comparable in therapeutic focus and as a similarly scaled pre-commercial GI company.

TypeEmerging player
Description

Clinical-stage microbiome therapeutics company with lead GI programs (Vowst, SER-109) — emerging player with partial overlap in novel GI therapeutic modalities and similar development-stage profile.

8Entrega Bio
TypeDirect peer
Description

Developer of a proprietary local drug delivery platform for GI and other tissues (acquired by BioNTech) — directly comparable technology approach to Intact's smart-gel localized delivery concept.

TypeDirect peer
Description

GI-focused specialty biopharma (IBSRELA/tenapanor, Xphozah) developing novel mechanism therapies for GI and cardiorenal disease — comparable therapeutic focus and mid-cap specialty pharma positioning.

TypeBroad incumbent
Description

Global biopharma with significant GI exposure through Humira/Skyrizi/Rinvoq in IBD and the former Allergan GI portfolio — broad incumbent operating across many GI indications Intact is targeting.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intact Therapeutics

Gastrointestinal Therapeuticsintacttherapeutics.com

Intact Therapeutics firmographics

Firmographics
Name
Intact Therapeutics
Legal name
Intact Therapeutics, Inc.
Website
https://intacttherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Intact Therapeutics industry classification

Industry
Product category
Gastrointestinal Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Localized drug delivery
  • Gastrointestinal therapeutics
  • Biopharmaceutical drug development
  • Clinical-stage biopharmaceuticals
  • Novel drug formulations

Where Intact Therapeutics is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Markets served

Intact Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Clinical-stage biopharmaceutical company developing innovative medicines for gastrointestinal disease. Revenue model likely to include pharmaceutical product sales upon regulatory approval, potentially through licensing agreements or direct commercialization.

Intact Therapeutics product offering

Product offering

Core offering

Intact Therapeutics is a clinical-stage biopharmaceutical company developing next-generation localized drug delivery technologies (smart gels / micelles-based formulations) for the treatment of gastrointestinal (GI) disease. The platform is designed to deliver therapeutics directly to GI tissue, addressing unmet clinical needs and aiming to improve efficacy and reduce systemic side effects relative to conventional systemic drug delivery. The company has no commercially approved products at this stage.

Product overview

Intact Therapeutics is a clinical-stage biopharmaceutical company developing next-generation localized drug delivery technologies for gastrointestinal (GI) disease. The company operates as a single-focus therapeutic development organization without modular products or a platform-plus-components architecture — its portfolio consists of innovative medicines in development targeting GI diseases, though specific named products are not publicly disclosed on the available source pages.

Differentiator

Problem solved

Functional benefit

Products and services

  • Localized Drug Delivery Platform (GI) Proprietary next-generation localized drug delivery platform (smart gels / micelles-based) designed for targeted treatment of gastrointestinal diseases. The platform is being developed to deliver therapeutics directly to GI tissue with the goal of improving efficacy and reducing systemic side effects relative to conventional systemic drug delivery. Currently pre-clinical / clinical-stage with no approved products.

Companies that use Intact Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Intact Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Intact Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Stanford University (SMC Stanford)coreStrategic or Co-development PartnerStanford University, specifically through its SMC (Stanford Medicine Consortium) program, partners with Intact Therapeutics for research collaboration, academic expertise, and potential co-development opportunities in drug delivery technology.
  • UCSF Rosenman InstitutecoreStrategic or Co-development PartnerThe UCSF Rosenman Institute, focused on health technology and innovation, provides strategic partnership for Intact Therapeutics including access to medical research expertise and potential clinical collaboration opportunities.
  • EncubeminorStrategic or Co-development PartnerEncube appears as a partner logo on the Intact Therapeutics website, indicating a strategic relationship possibly related to pharmaceutical development, manufacturing, or commercialization support.

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Intact Therapeutics competitors and assessment

Company assessment

Direct peers

  • Ironwood Pharmaceuticals: Specialty GI biopharmaceutical company (Linzess/linaclotide) focused on GI diseases — directly comparable in therapeutic area and stage evolution, though at a far larger commercial scale.
  • RedHill Biopharma: Specialty biopharma with a GI-dominant commercial portfolio (Talicia, Aemcolo) and pipeline — directly comparable as a small/mid-cap GI specialty therapeutics developer.
  • Phathom Pharmaceuticals: Late-stage GI specialty biopharma (Voquezna for H. pylori and erosive esophagitis) — comparable in therapeutic focus and as a similarly scaled pre-commercial GI company.
  • Entrega Bio: Developer of a proprietary local drug delivery platform for GI and other tissues (acquired by BioNTech) — directly comparable technology approach to Intact's smart-gel localized delivery concept.
  • Ardelyx: GI-focused specialty biopharma (IBSRELA/tenapanor, Xphozah) developing novel mechanism therapies for GI and cardiorenal disease — comparable therapeutic focus and mid-cap specialty pharma positioning.

Emerging players

  • Synlogic: Clinical-stage synthetic biology company developing engineered probiotics for GI disorders (e.g., phenylketonuria, IBD) — emerging player using novel biology to address GI unmet need, comparable in stage and innovation orientation.
  • Seres Therapeutics: Clinical-stage microbiome therapeutics company with lead GI programs (Vowst, SER-109) — emerging player with partial overlap in novel GI therapeutic modalities and similar development-stage profile.

Broad incumbents

  • Takeda Pharmaceutical: Major global biopharma with a leading GI franchise including Entyvio for IBD — broad incumbent comparable in target indications but vastly larger and broader in scope.
  • Bausch Health (Salix): Through its Salix franchise, Bausch is a dominant established GI specialty pharma player — relevant incumbent comparable in therapeutic area but not in scale or technology specificity.
  • AbbVie: Global biopharma with significant GI exposure through Humira/Skyrizi/Rinvoq in IBD and the former Allergan GI portfolio — broad incumbent operating across many GI indications Intact is targeting.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Intact Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intact Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Intact Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intact Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intact Therapeutics

What does Intact Therapeutics do?

Intact Therapeutics is a clinical-stage biopharmaceutical company developing next-generation localized drug delivery technologies (smart gels / micelles-based formulations) for the treatment of gastrointestinal (GI) disease. The platform is designed to deliver therapeutics directly to GI tissue, addressing unmet clinical needs and aiming to improve efficacy and reduce systemic side effects relative to conventional systemic drug delivery. The company has no commercially approved products at this stage.

Is Intact Therapeutics a public or private company?

Intact Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Intact Therapeutics founded?

Intact Therapeutics was founded in 2015. It employs 1 to 10 people.

Where is Intact Therapeutics based?

Intact Therapeutics is headquartered in Palo Alto, United States, in the North America region.

How does Intact Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Intact Therapeutics's main competitors?

Direct peers on record are Ironwood Pharmaceuticals, RedHill Biopharma, Phathom Pharmaceuticals, Entrega Bio and Ardelyx. Emerging players are Synlogic and Seres Therapeutics. Broad incumbents are Takeda Pharmaceutical, Bausch Health (Salix) and AbbVie.

Does Intact Therapeutics have an API?

No public API is recorded for Intact Therapeutics.

What industry is Intact Therapeutics in?

Intact Therapeutics's product category is Gastrointestinal Therapeutics. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales